期刊文献+

微管不稳定蛋白和Endoglin在大肠癌组织中的表达 被引量:7

Significance and expression of stathmin and endoglin in colorectal carcinoma
原文传递
导出
摘要 目的 探讨微管不稳定蛋白(Stathmin)和Endoglin标记的微血管密度计数(MVD)在大肠癌中的表达及其与临床病理学参数之间的关系.方法 收集46例大肠癌患者手术切除的肿瘤组织和癌旁组织,运用免疫组织化学法检测Stathmin和Endoglin标记的MVD在组织中表达水平.结果 Stathmin大肠癌组织的表达率为69.57% (32/46),明显高于癌旁组织表达率[34.78% (16/46)],两者差异有统计学意义(P<0.01),Stathmin表达水平与大肠癌组织学分化程度、浸润深度、TNM分期、淋巴结转移明显相关(P<0.05);Endoglin标记的MVD大肠癌组织的表达强度为(68.27±5.66)个,明显高于癌旁组织的表达强度[(41.51±4.52)个],两者差异有统计学意义(P<0.01);Endoglin标记的MVD表达强度与大肠癌浸润深度、TNM分期、淋巴结转移明显相关(P<0.05).结论 联合检测Stathmin和Endoglin有助于判断大肠癌临床生物学行为. Objective To analyze the relationship between the expression of Stathmin and endoglin-marked microvessel density (MVD) and clinicopathological features of colorectal carcinoma.Methods Immunohistochemistry was used to detect the expression levels of Stathmin and MVD marked with endoglin in 46 cases of human colorectal carcinoma tissues and non-cancerous adjacent colorectal tissues.Results The expression rate of Stathmin was 69.57% (32/46) in colorectal carcinoma tissues,and 34.78%(16/46) in non-cancerous adjacent colorectal tissues (P 〈0.01).The expression of Stathmin was related to histologic grade,serosa invasion,TNM stage and lymph node metastasis in colorectal carcinoma (P 〈0.05).The expression of MVD marked with endoglin was (68.27 ± 5.66) in colorectal carcinoma tissues,and (41.51 ±4.52) in non-cancerous adjacent colorectal tissues (P 〈0.01).The expression of MVD was related to serosa invasion,TNM stage and lymph node metastasis (P 〈 0.05).Conclusion The combined detection of Stathmin and endoglin may be used to determine the biological behaviors of colorectal carcinoma.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2014年第2期266-268,共3页 Chinese Journal of Experimental Surgery
关键词 微管不稳定蛋白 ENDOGLIN 微血管密度 大肠癌 Stathmin Endoglin Microvessel density Colorectal carcinoma
  • 相关文献

参考文献8

二级参考文献27

  • 1杨祖立,汪建平,元云飞,蔡世荣,黄美近.结直肠癌侵袭性与脾酪氨酸激酶基因Syk启动子甲基化的关系[J].中华实验外科杂志,2005,22(1):68-70. 被引量:32
  • 2马军,郭敏,李印,唐芙爱,虎建恩,段芳龄.食管鳞癌中TGF-β及其受体调节成分Endoglin/CD105的表达[J].第四军医大学学报,2006,27(14):1308-1311. 被引量:4
  • 3张水军,李文涛,周闯,赵龙拴,范正军.抑癌基因TSLC1在肝癌组织中的表达及临床意义[J].中华实验外科杂志,2007,24(2):185-186. 被引量:9
  • 4Saad RS, Liu YL, Nathan G,, et al. Endoglin ( CD105 ) and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod Patho1,2004,17 : 197-203.
  • 5Kumar S, Ghellal A, Li C, et al. Breast carcinoma: vascular density de- termined using CD105 antibody correlates with tumor prognosis. Cancer Res, 1999,59:856-861.
  • 6Sehimming R, Marine D. Endoglin(CD105) expression in squamous cell carcinoma of the oral cavity. Head Neck ,2002,24:151-156.
  • 7Munoz R, Arias Y, Ferreras JM, et al. Targeting a marker of the tumour neovasculature using a novel anti-human CDlOS-immanotoxin containing the non-toxic type2 ribosome-inactivating protein nigrinb. Cancer Lett, 2007,256 : 73 -80.
  • 8Lee SH, Mizutani N, Mizutani M ,et al. Endoglin (CD105) is a target for an oral DNA vaccine against breast cancer. Cancer Immunol Immunother, 2006,55 : 1565 -1574.
  • 9Seon BK Takahashi N, Haba A, et al. Angiogenesis and metastasis marker of human tumors. Rinsho Byori ,2001,49 : 1005-1013.
  • 10Bellone G, Solerio D, Chiusa L, et al. Transforming growth factor-beta binding receptor endoglin ( CD105 ) expression in esophageal cancer and in adjacent nontumorous esophagus as prognostic predictor of recurrence [ J ]. Ann Surg Oncol, 2007,14 ( 11 ) :3232 - 3242.

共引文献38

同被引文献58

引证文献7

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部